Red blood cell contamination of the final cell product impairs the efficacy of autologous bone marrow mononuclear cell therapy
- PMID: 20338501
- DOI: 10.1016/j.jacc.2009.10.059
Red blood cell contamination of the final cell product impairs the efficacy of autologous bone marrow mononuclear cell therapy
Abstract
Objectives: The aim of this study was to identify an association between the quality and functional activity of bone marrow-derived progenitor cells (BMCs) used for cardiovascular regenerative therapies and contractile recovery in patients with acute myocardial infarction included in the placebo-controlled REPAIR-AMI (Reinfusion of Enriched Progenitor cells And Infarct Remodeling in Acute Myocardial Infarction) trial.
Background: Isolation procedures of autologous BMCs might affect cell functionality and therapeutic efficacy.
Methods: Quality of cell isolation was assessed by measuring the total number of isolated BMCs, CD34+ and CD133+ cells, their colony-forming unit (CFU) and invasion capacity, cell viability, and contamination of the final BMC preparation with thrombocytes and red blood cells (RBCs).
Results: The number of RBCs contaminating the final cell product significantly correlated with reduced recovery of left ventricular ejection fraction 4 months after BMC therapy (p = 0.007). Higher numbers of RBCs in the BMC preparation were associated with reduced BMC viability (r = -0.23, p = 0.001), CFU capacity (r = -0.16, p = 0.03), and invasion capacity (r = -0.27, p < 0.001). To assess a causal role for RBC contamination, we coincubated isolated BMCs with RBCs for 24 h in vitro. The addition of RBCs dose-dependently abrogated migratory capacity (p = 0.003) and reduced CFU capacity (p < 0.05) of isolated BMCs. Neovascularization capacity was significantly impaired after infusion of BMCs contaminated with RBCs, compared with BMCs alone (p < 0.05). Mechanistically, the addition of RBCs was associated with a profound reduction in mitochondrial membrane potential of BMCs.
Conclusions: Contaminating RBCs affects the functionality of isolated BMCs and determines the extent of left ventricular ejection fraction recovery after intracoronary BMC infusion in patients with acute myocardial infarction. These results suggest a bioactivity response relationship very much like a dose-response relationship in drug trials. (Reinfusion of Enriched Progenitor cells and Infarct Remodeling in Acute Myocardial Infarction [REPAIR-AMI]; NCT00279175).
Similar articles
-
Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction.Eur Heart J. 2007 Mar;28(6):766-72. doi: 10.1093/eurheartj/ehl509. Epub 2007 Feb 13. Eur Heart J. 2007. PMID: 17298974
-
Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE-AMI): mechanistic insights from serial contrast-enhanced magnetic resonance imaging.Circulation. 2003 Nov 4;108(18):2212-8. doi: 10.1161/01.CIR.0000095788.78169.AF. Epub 2003 Oct 13. Circulation. 2003. PMID: 14557356 Clinical Trial.
-
Restoration of microvascular function in the infarct-related artery by intracoronary transplantation of bone marrow progenitor cells in patients with acute myocardial infarction: the Doppler Substudy of the Reinfusion of Enriched Progenitor Cells and Infarct Remodeling in Acute Myocardial Infarction (REPAIR-AMI) trial.Circulation. 2007 Jul 24;116(4):366-74. doi: 10.1161/CIRCULATIONAHA.106.671545. Epub 2007 Jul 9. Circulation. 2007. PMID: 17620510 Clinical Trial.
-
Is the measurement of left ventricular ejection fraction the proper end point for cell therapy trials? An analysis of the effect of bone marrow mononuclear stem cell administration on left ventricular ejection fraction after ST-segment elevation myocardial infarction when evaluated by cardiac magnetic resonance imaging.Am Heart J. 2011 Oct;162(4):671-7. doi: 10.1016/j.ahj.2011.06.019. Am Heart J. 2011. PMID: 21982659 Review.
-
[Stem cells after myocardial infarction].Herz. 2006 Apr;31(2):127-36; quiz 142-3. doi: 10.1007/s00059-006-2794-x. Herz. 2006. PMID: 16738836 Review. German.
Cited by
-
Granulocyte-colony stimulating factor therapy improves survival in patients with hepatitis B virus-associated acute-on-chronic liver failure.World J Gastroenterol. 2013 Feb 21;19(7):1104-10. doi: 10.3748/wjg.v19.i7.1104. World J Gastroenterol. 2013. PMID: 23467275 Free PMC article. Clinical Trial.
-
Effective Label-Free Sorting of Multipotent Mesenchymal Stem Cells from Clinical Bone Marrow Samples.Bioengineering (Basel). 2022 Jan 22;9(2):49. doi: 10.3390/bioengineering9020049. Bioengineering (Basel). 2022. PMID: 35200403 Free PMC article.
-
Evaluation of post-thaw CFU-GM: clinical utility and role in quality assessment of umbilical cord blood in patients receiving single unit transplant.Transfusion. 2020 Jan;60(1):144-154. doi: 10.1111/trf.15592. Epub 2019 Nov 22. Transfusion. 2020. PMID: 31756003 Free PMC article. Clinical Trial.
-
Human Leukocyte Antigen and Red Blood Cells Impact Umbilical Cord Blood CD34+ Cell Viability after Thawing.Int J Mol Sci. 2019 Sep 30;20(19):4875. doi: 10.3390/ijms20194875. Int J Mol Sci. 2019. PMID: 31575081 Free PMC article.
-
Evaluation of bone marrow mononuclear cells as an adjunct therapy to minced muscle graft for the treatment of volumetric muscle loss injuries.Stem Cell Res Ther. 2017 Jun 9;8(1):142. doi: 10.1186/s13287-017-0589-z. Stem Cell Res Ther. 2017. PMID: 28599679 Free PMC article.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials